1. Home
  2. XPRO vs URGN Comparison

XPRO vs URGN Comparison

Compare XPRO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expro Group Holdings N.V.

XPRO

Expro Group Holdings N.V.

HOLD

Current Price

$16.14

Market Cap

1.9B

Sector

Energy

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$38.20

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPRO
URGN
Founded
1938
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2026
2016

Fundamental Metrics

Financial Performance
Metric
XPRO
URGN
Price
$16.14
$38.20
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
$16.00
$29.29
AVG Volume (30 Days)
1.0M
681.9K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$1.86
$129.09
Revenue Next Year
$4.70
$70.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.81
$15.86
52 Week High
$18.73
$43.93

Technical Indicators

Market Signals
Indicator
XPRO
URGN
Relative Strength Index (RSI) 51.30 51.19
Support Level $15.25 $18.23
Resistance Level $17.09 $43.93
Average True Range (ATR) 0.86 1.92
MACD -0.07 -0.52
Stochastic Oscillator 45.98 11.72

Price Performance

Historical Comparison
XPRO
URGN

About XPRO Expro Group Holdings N.V.

Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: